share_log

Hercules Capital Analyst Ratings

Benzinga Analyst Ratings ·  Oct 3, 2022 07:53
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
10/03/2022 12.36% Piper Sandler $16 → $13 Maintains Neutral
08/01/2022 55.57% JMP Securities $19 → $18 Maintains Market Outperform
07/29/2022 29.65% Oppenheimer $18 → $15 Downgrades Outperform → Perform
06/28/2022 33.97% Piper Sandler $18.5 → $15.5 Maintains Neutral
04/25/2022 64.22% Wells Fargo $18.5 → $19 Maintains Overweight
04/22/2022 55.57% Keefe, Bruyette & Woods → $18 Downgrades Outperform → Market Perform
04/04/2022 64.22% Piper Sandler → $19 Downgrades Overweight → Neutral
02/08/2022 55.57% Compass Point → $18 Downgrades Buy → Neutral
04/28/2021 51.25% Oppenheimer → $17.5 Initiates Coverage On → Outperform
03/25/2021 46.93% RBC Capital → $17 Initiates Coverage On → Outperform
10/09/2020 12.36% Piper Sandler $12 → $13 Maintains Overweight
09/09/2020 12.36% JMP Securities $12.5 → $13 Maintains Market Outperform
07/31/2020 10.2% Compass Point $10.25 → $12.75 Upgrades Neutral → Buy
06/19/2020 10.2% Janney Montgomery Scott → $12.75 Upgrades Neutral → Buy
05/13/2020 16.68% Wedbush $15 → $13.5 Maintains Outperform
05/05/2020 8.04% JMP Securities $16.5 → $12.5 Maintains Market Outperform
05/05/2020 3.72% B. Riley Securities $11 → $12 Maintains Buy
04/27/2020 -2.77% Wells Fargo $10.75 → $11.25 Maintains Overweight
04/06/2020 -13.57% Piper Sandler $16 → $10 Maintains Overweight
03/25/2020 -7.09% Wells Fargo $16.5 → $10.75 Maintains Overweight
03/24/2020 -4.93% B. Riley Securities $17 → $11 Maintains Buy
02/26/2020 42.61% JMP Securities $15 → $16.5 Maintains Market Outperform
02/21/2020 46.93% B. Riley Securities $15 → $17 Maintains Buy
11/04/2019 Wells Fargo Upgrades Market Perform → Outperform
05/06/2019 Wells Fargo Downgrades Outperform → Market Perform
05/03/2019 29.65% B. Riley Securities $11.5 → $15 Upgrades Neutral → Buy
03/13/2019 -0.61% B. Riley Securities $15 → $11.5 Downgrades Buy → Neutral
03/13/2019 Keefe, Bruyette & Woods Downgrades Outperform → Market Perform
03/13/2019 Compass Point Downgrades Buy → Neutral
11/05/2018 21% Wells Fargo $14.25 → $14 Maintains Outperform
08/16/2018 25.32% JMP Securities $14 → $14.5 Maintains Market Outperform
08/06/2018 29.65% Wedbush $13.75 → $15 Maintains Outperform
02/07/2018 Wedbush Upgrades Neutral → Outperform
11/20/2017 25.32% Ladenburg Thalmann → $14.5 Initiates Coverage On → Buy
11/03/2017 Raymond James Upgrades Underperform → Market Perform
10/25/2017 14.52% Wedbush → $13.25 Initiates Coverage On → Neutral

Hercules Capital Questions & Answers

What is the target price for Hercules Capital (HTGC)?

The latest price target for Hercules Capital (NYSE: HTGC) was reported by Piper Sandler on October 3, 2022. The analyst firm set a price target for $13.00 expecting HTGC to rise to within 12 months (a possible 12.36% upside). 8 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Hercules Capital (HTGC)?

The latest analyst rating for Hercules Capital (NYSE: HTGC) was provided by Piper Sandler, and Hercules Capital maintained their neutral rating.

When is the next analyst rating going to be posted or updated for Hercules Capital (HTGC)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Hercules Capital, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Hercules Capital was filed on October 3, 2022 so you should expect the next rating to be made available sometime around October 3, 2023.

Is the Analyst Rating Hercules Capital (HTGC) correct?

While ratings are subjective and will change, the latest Hercules Capital (HTGC) rating was a maintained with a price target of $16.00 to $13.00. The current price Hercules Capital (HTGC) is trading at is $11.57, which is out of the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment